# Proto Labs Inc. (PRLB) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Industrials / Machinery. Price $69.10, market value $1.6 billion.

## Valuation
- **P/E (trailing): 48.0×** (5-yr avg 54.5×, 3-yr avg 58.6×). Proto Labs Inc. trades at 48.0× trailing earnings, close to its own five-year average of 54.5×. The Industrials median in the September 2026 study was 25.7×. Forward P/E is 27.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.83**. A PEG of 0.83 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.8×**. Each dollar of revenue is priced at 2.8×.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 20.6×**. Enterprise value is 20.6× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.9%** (5-yr avg 4.7%). Free cash flow equals 2.9% of the market value, below its five-year average of 4.7%, so the shares are pricier on cash than usual.
- **Earnings yield: 2.1%**. The inverse of the P/E: 2.1% of the price is earned each year.

## Profitability
- **Gross margin: 45.2%**. Proto Labs Inc. keeps 45.2% of revenue after the direct cost of what it sells.
- **Operating margin: 7.3%**. 7.3% of revenue is left after running the business.
- **Net margin: 4.0%**. 4.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 3.2%**. 3.2% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 6.0%**. Return on all capital, debt included, is 6.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 4.6%**. Each dollar of assets produces 4.6% of profit.

## Growth
- **Revenue growth (1 yr): 6.4%** (3-yr 3.0%/yr, 5-yr 4.2%/yr). Revenue grew 6.4% over the last year, against 4.2% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 33.3%** (5-yr -14.2%/yr). Earnings per share rose 33.3%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 13.9%/yr**. Free cash flow has compounded at 13.9% a year over three years.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Proto Labs Inc. holds more cash than debt.
- **Current ratio: 3.49** (quick 3.49). Current assets cover the next year's liabilities 3.49 times.
- **Altman Z-score: 13.37**. A Z-score of 13.37 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Proto Labs Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (4 analysts). 4 analysts cover Proto Labs Inc.; the consensus is buy, with an average price target of $101.25 (+47% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 35.1%** (YTD 32.9%, 3-mo -16.2%). The shares are up 35.1% over twelve months including dividends.
- **From 52-week high: -30.9%** (50.0% above the low). Trading 31% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 27**. An RSI of 27 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 2.17** (volatility 51%). Beta of 2.17 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PRLB · Page: https://foliofundamentals.com/stocks/prlb

Not investment advice.